Related Experiment Video
Updated: Aug 21, 2025
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
Gadolinium-Bisphosphonate Nanoparticle-Based Low-Dose Radioimmunotherapy for Osteosarcoma.
Shaodian Zhang1,2, Yanxian Wu1, Jiangkun Yu1
1School of Radiation Medicine and Protection, State Key Laboratory of Radiation Medicine and Protection, School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou 215123, P. R. China.
Novel gadolinium-based nanoparticles (OVA-GdZol NPs) enhance radiotherapy for osteosarcoma by sensitizing cancer cells and activating the immune system, leading to reduced tumor growth and metastasis.
Area of Science:
- Biomedical Engineering
- Nanomedicine
- Cancer Therapy
Background:
- Osteosarcoma is a highly metastatic bone cancer common in adolescents.
- Radiotherapy for osteosarcoma requires high doses, potentially suppressing the immune system.
- Novel agents are needed to enhance radiotherapy efficacy through immune activation.
Purpose of the Study:
- To develop and evaluate gadolinium-based metal-bisphosphonate nanoparticles (OVA-GdZol NPs) for osteosarcoma treatment.
- To investigate OVA-GdZol NPs as radiosensitizers and immune adjuvants.
- To assess the combined therapeutic effect of OVA-GdZol NPs and radiotherapy.
Main Methods:
- Synthesis of ovalbumin-stabilized gadolinium-zoledronic acid nanoparticles (OVA-GdZol NPs).
- In vitro studies on K7M2 osteosarcoma cells to assess radiosensitization (colony reduction, γH2AX staining).
- In vivo studies evaluating tumor growth, metastasis, survival rates, and immune responses (dendritic cell maturation, macrophage polarization).
Main Results:
- OVA-GdZol NPs were internalized by osteosarcoma cells and enhanced radiosensitivity in vitro.
- NPs promoted dendritic cell maturation and M1 macrophage polarization.
- Combined treatment significantly reduced tumor volume, decreased lung metastasis, and improved survival rates.
- Innate and adaptive immune systems were activated, contributing to antitumor effects.
Conclusions:
- OVA-GdZol NPs act as effective radiosensitizers and immune adjuvants for osteosarcoma.
- This nanoparticle-based approach shows promise for sequential vaccination and radiotherapy combinations.
- The findings support the development of novel nanomedicines for enhanced cancer immunotherapy.
